These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 34579226)

  • 1. Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3.
    Fan YJ; Chan KH; Hung IF
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.
    Lee ARYB; Wong SY; Chai LYA; Lee SC; Lee MX; Muthiah MD; Tay SH; Teo CB; Tan BKJ; Chan YH; Sundar R; Soon YY
    BMJ; 2022 Mar; 376():e068632. PubMed ID: 35236664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of COVID-19 inactivated vaccine: A meta-analysis.
    Li X; Yang X; Ning Z
    Front Med (Lausanne); 2022; 9():1015184. PubMed ID: 36419789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project).
    Korang SK; Juul S; Nielsen EE; Feinberg J; Siddiqui F; Ong G; Klingenberg S; Veroniki AA; Bu F; Thabane L; Thomsen AR; Jakobsen JC; Gluud C
    Syst Rev; 2020 Nov; 9(1):262. PubMed ID: 33218366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis.
    Stefanou MI; Palaiodimou L; Theodorou A; Christodoulou MV; Tzartos JS; Tzanetakos D; Kitsos D; Chondrogianni M; Zouvelou V; Dardiotis E; Tzavellas E; Syrigou E; Benetou V; Paraskevas GP; Tsiodras S; Tsivgoulis G; Giannopoulos S
    Mult Scler; 2023 Apr; 29(4-5):585-594. PubMed ID: 36722184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
    Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
    JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
    Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang H; Wang W; Zhang W; Li N; Xie Z; Ding L; You W; Zhao Y; Yang X; Liu Y; Wang Q; Huang L; Yang Y; Xu G; Luo B; Wang W; Liu P; Guo W; Yang X
    Lancet Infect Dis; 2021 Jan; 21(1):39-51. PubMed ID: 33069281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis.
    Chen L; Cai X; Zhao T; Han B; Xie M; Cui J; Zhang J; Wang C; Liu B; Lu Q; Cui F
    Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis.
    Cheng H; Peng Z; Luo W; Si S; Mo M; Zhou H; Xin X; Liu H; Yu Y
    Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34206032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19: Coronavirus Vaccine Development Updates.
    Zhao J; Zhao S; Ou J; Zhang J; Lan W; Guan W; Wu X; Yan Y; Zhao W; Wu J; Chodosh J; Zhang Q
    Front Immunol; 2020; 11():602256. PubMed ID: 33424848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, Efficacy, and Immunogenicity of Varying Types of COVID-19 Vaccines in Children Younger Than 18 Years: An Update of Systematic Review and Meta-Analysis.
    Tian Y; Chen L; Shi Y
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.
    Li XN; Huang Y; Wang W; Jing QL; Zhang CH; Qin PZ; Guan WJ; Gan L; Li YL; Liu WH; Dong H; Miao YT; Fan SJ; Zhang ZB; Zhang DM; Zhong NS
    Emerg Microbes Infect; 2021 Dec; 10(1):1751-1759. PubMed ID: 34396940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Seroconversion of Immunotherapies against SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis of Clinical Trials.
    Ma KS; Lee CC; Liu KJ; Wei JC; Lee YT; Wang LT
    Pathogens; 2021 Nov; 10(12):. PubMed ID: 34959492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
    Barda N; Dagan N; Ben-Shlomo Y; Kepten E; Waxman J; Ohana R; Hernán MA; Lipsitch M; Kohane I; Netzer D; Reis BY; Balicer RD
    N Engl J Med; 2021 Sep; 385(12):1078-1090. PubMed ID: 34432976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review the safety of Covid-19 mRNA vaccines: a review.
    Anand P; Stahel VP
    Patient Saf Surg; 2021 May; 15(1):20. PubMed ID: 33933145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2.
    Baldo A; Leunda A; Willemarck N; Pauwels K
    Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34063733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
    Sharma O; Sultan AA; Ding H; Triggle CR
    Front Immunol; 2020; 11():585354. PubMed ID: 33163000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.